{"filing":{"accession_number":"0001213900-26-086120","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ea0300898-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026086120/ea0300898-6k_clearmind.htm"},"events":[{"id":24547,"run_id":22255,"accession_number":"0001213900-26-086120","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a key clinical development milestone: DSMB unanimous approval to advance Clearmind's Phase I/II trial of CMND-100 from Part A (healthy participants) to Parts B and C, with Part B marking the first evaluation in AUD patients. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents meaningful progress in the regulatory pathway and de-risks the clinical program. The language (\"key milestone,\" \"important milestone,\" advancement to patient population) and the involvement of leading clinical sites (Johns Hopkins, Yale) underscore materiality to investors assessing the company's development trajectory.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":25142,"accession_number":"0001213900-26-086120","item_number":"EX-99.1","item_title":"ea030089802ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a key clinical development milestone: DSMB unanimous approval to advance Clearmind's Phase I/II trial of CMND-100 from Part A (healthy participants) to Parts B and C, with Part B marking the first evaluation in AUD patients. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents meaningful progress in the regulatory pathway and de-risks the clinical program. The language (\"key milestone,\" \"important milestone,\" advancement to patient population) and the involvement of leading clinical sites (Johns Hopkins, Yale) underscore materiality to investors assessing the company's development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:08:56.962402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25142,"accession_number":"0001213900-26-086120","item_number":"EX-99.1","item_title":"ea030089802ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a key clinical development milestone: DSMB unanimous approval to advance Clearmind's Phase I/II trial of CMND-100 from Part A (healthy participants) to Parts B and C, with Part B marking the first evaluation in AUD patients. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents meaningful progress in the regulatory pathway and de-risks the clinical program. The language (\"key milestone,\" \"important milestone,\" advancement to patient population) and the involvement of leading clinical sites (Johns Hopkins, Yale) underscore materiality to investors assessing the company's development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:08:56.962402+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-08-06"}]}